Vitamin D Receptor Activation Down-regulates the Small Heterodimer Partner and Increases CYP7A1 to Lower Cholesterol

Dec 25, 2013Gastroenterology

Activating vitamin D receptors lowers cholesterol by reducing a regulator and increasing an enzyme that breaks down cholesterol

AI simplified

Abstract

Injection of 1,25(OH)2D3 reduced cholesterol levels in hypercholesterolemic mice.

  • Activation of the vitamin D receptor (VDR) is linked to increased expression of cholesterol 7α-hydroxylase (CYP7A1) in both mouse and human hepatocytes.
  • In mice, hepatic CYP7A1 mRNA and protein levels rose in response to 1,25(OH)2D3 treatment, while small heterodimer partner (SHP) mRNA levels decreased.
  • Changes in hepatic CYP7A1 mRNA were associated with alterations in CYP24A1 mRNA, a target gene of VDR, but not with ileal fibroblast growth factor 15 (Fgf15) mRNA.
  • In wild-type and Fxr(-/-) mice, 1,25(OH)2D3 treatment led to decreased plasma and liver cholesterol levels.
  • VDR directly binds to regions of the SHP promoter, inhibiting its expression, which may facilitate the increase in CYP7A1.

AI simplified

Full Text

Full text is available at the source.

what lands in your inbox each week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free